Premium
Case‐control analysis of survival outcomes in sinonasal acinic cell carcinoma
Author(s) -
Biron Vincent L.,
Lentsch Eric J.,
Gerry Daniel R.,
Bewley Arnaud F.
Publication year - 2014
Publication title -
international forum of allergy and rhinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.503
H-Index - 46
eISSN - 2042-6984
pISSN - 2042-6976
DOI - 10.1002/alr.21301
Subject(s) - acinic cell carcinoma , medicine , parotid gland , epidemiology , retrospective cohort study , cohort , salivary gland , cancer , oncology , salivary gland cancer , stage (stratigraphy) , survival analysis , surveillance, epidemiology, and end results , pathology , mucoepidermoid carcinoma , cancer registry , paleontology , biology
Background Acinic cell carcinoma (AciCC) is an uncommon malignant‐epithelial salivary gland cancer. In very rare cases, this tumor may arise from sinonasal subsites, with only 19 cases described in the English‐language literature. Methods We performed a retrospective analysis of 18 cases of AciCC, obtained from searching the Surveillance, Epidemiology, and End Results (SEER) database between 1973 and 2009. Results Patient demographics, including age, gender, and race, were similar to AciCC cases found in more common locations. However, all patients had low‐grade tumors without regional or distant metastases. Comparing these patients to a stage, grade, and treatment–matched cohort of parotid AciCC, we found a lower 10‐year overall survival (52.3%) with no significant difference in disease‐specific survival (88.9%). Our meta‐analysis of survival from cases in the literature estimated 10‐year recurrence‐free survival at 92.9%. Conclusion To our knowledge, this is the largest cohort of patients with AciCC reported in the English‐language literature. Our results suggest that patients with sinonasal AciCC have excellent disease‐specific survival, comparable to matched patients with AciCC in more common salivary gland subsites.